Sanofi's Venglustat Phase 3 Trial Targets Left Ventricular Mass in Fabry Disease
Sanofi is conducting Phase 3 trial to assess the efficacy of venglustat on left ventricular mass index in Fabry disease patients.
Asset / Drug
Drug and asset intelligence for Venglustat with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.